Riliprubart |
| Katalog-Nr.GC72326 |
Riliprubart (SAR445088) ist ein humanisierter monoklonaler Antikörper gegen C1s, der aktivierte C1s im proximalen Teil des klassischen Komplementsystems hemmt.
Products are for research use only. Not for human use. We do not sell to patients.
Cas No.: 2756228-76-7
Sample solution is provided at 25 µL, 10mM.
;)
,-1-7$$$37316672.jpg');)
;)
;)
$$$36806353.jpg');)
;33(7)%EF%BC%9A546-561$$$37156877.jpg');)
;)
;)
;)
%201124-1138.$$$35908550.jpg');)
%20766-780.$$$37100057.jpg');)
%20418-432.$$$36893736.jpg');)
%EF%BC%9A-240-255.$$$35108512.jpg');)
533-545$$$36543525.jpg');)
%201-13.$$$36600053.jpg');)
;)
Riliprubart (SAR445088) is an anti-C1s humanized monoclonal antibody that inhibits activated C1s in the proximal portion of the classical complement system. Riliprubart selectively inhibits activated C1s and prevents the enzymatic action of C1 on its substrates C4 and C2, thus inhibiting the formation of the classical pathway C3 convertase, C4b2a.
References:
[1]. Timothy Chow, et al. First-in-human study with SAR445088: A novel selective classical complement pathway inhibitor. Clin Transl Sci. 2023 Apr;16(4):673-685.
Review for Riliprubart
Average Rating: 5 (Based on Reviews and 30 reference(s) in Google Scholar.)
Review for Riliprubart
GLPBIO products are for RESEARCH USE ONLY. Please make sure your review or question is research based.
Required fields are marked with *